Regulatory B Cell Therapy in Kidney Transplantation

Sergio G. Garcia¹,²†, Noelia Sandoval-Hellín¹† and Marcella Franquesa¹*

¹REMAR-IGTP Group, Germans Trias i Pujol Research Institute (IGTP) and Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus, Badalona (Barcelona), Catalonia, Spain, ²Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Bellaterra, Spain

In the context of kidney injury, the role of Bregs is gaining interest. In a number of autoimmune diseases, the number and/or the function of Bregs has been shown to be impaired or downregulated, therefore restoring their balance might be a potential therapeutic tool. Moreover, in the context of kidney transplantation their upregulation has been linked to tolerance. However, a specific marker or set of markers that define Bregs as a unique cell subset has not been found and otherwise multiple phenotypes of Bregs have been studied. A quest on the proper markers and induction mechanisms is now the goal of many researchers. Here we summarize the most recent evidence on the role of Bregs in kidney disease by describing the relevance of in vitro and in vivo Bregs induction as well as the potential use of Bregs as cell therapy agents in kidney transplantation.

Keywords: regulatory B cells, kidney transplantation, graft tolerance, cell therapy, immunosuppressive therapy

INTRODUCTION

B cells are traditionally described to show a primarily effector phenotype: antibody-producing cells with the capacity to present antigen and stimulate T cells through cytokine production (Janeway et al., 1987; Ochsenbein et al., 1999; Harris et al., 2000). However, nowadays it is widely accepted the existence of B cell subsets with regulatory phenotypes (Bregs) involved in suppressing the immune response, inducing tolerance and maintaining homeostasis (Wang et al., 2020). Immunomodulatory functions of Bregs could be mediated by the action of soluble molecules such as IL-10, IL-35, TGF-β or Granzyme B or by cell contact-dependent apoptosis-inducing mechanisms such as PD-L1, FasL or TIGIT (Flores-Borja et al., 2013; Tang et al., 2016; Cai et al., 2019; Chesneau et al., 2020).

Despite essential roles in modulating several diseases, Bregs so far are not known to have a unique or exclusive marker that defines them as a population, but they constitute a heterogeneous cell population that possess a regulatory phenotype and can be found at different stages of B-cell development as reviewed in (Rosser and Mauri, 2015; Oleinika et al., 2019; Long et al., 2021). However, several markers have been proposed as enriched or identifiers of Breg populations. Breg are commonly identified by their expression of IL-10, with transitional phenotypes, CD19⁺CD24HiCD38Hi, as the most abundant phenotype in peripheral blood. Nevertheless, since the initial description of IL-10 + Breg, other populations such as plasmablast (CD19⁺CD27⁺CD38⁺), regulatory B1 cells (CD19⁺CD25⁺CD71⁺CD73⁺) and memory IL-10⁺ B cells (CD19⁺CD24HiCD27⁺IL-10⁺) have been described as Breg subsets, and different effector molecules have been linked to regulatory B cells identification and function, such as Tim-1, CD5, CD1d, CD25, GMZB, FasL, CD71, etc. as summarized in Table 1.

The classic conception of the role of B cells in the field of transplantation was called into question in the last decade, following the publication of two simultaneous studies in 2010, highlighting the
relevance of B cells in the development of tolerance in renal transplantation. Both studies involved transplant recipients who had developed spontaneous tolerance and stable patients receiving immunosuppressive therapy. The results obtained in "spontaneously tolerant" patients showed the presence of a higher percentage of B cells in peripheral blood, especially naïve and transitional B cells. At the same time, a higher expression of genes involved in B-cell development was also detected in these tolerant patients compared to stable patients on immunosuppressive therapy (Newell et al., 2010; Sagoo et al., 2010).

Since the emergence of these breakthrough results in 2010, the effect of Breg on the development of tolerance has been described several times as reviewed in (Peng et al., 2018; Cherukuri et al., 2021; Long et al., 2021).

The putative tolerance-inducing power of Bregs makes them an interesting target for the development of therapies to combat transplanted kidney rejection. Among the possible treatment strategies that could be considered, two main groups can be distinguished: those aimed at boosting the natural population of Bregs in the donor and, alternatively, therapy based on the transfer of previously expanded or modified Breg in vitro. Here we summarize the most recent evidence on the role of Bregs in kidney transplantation by describing the relevance of in vitro and in vivo induced Breg (iBreg) as well as the potential use of Bregs as cell therapy agents.

### IN VIVO BREGS INDUCTION

Several therapeutic strategies have been proposed or found to induce Breg in vitro and in vivo in human patients, both in preclinical and clinical trials, despite the aforementioned difficulty of accurately identify Breg. In the following section we discuss the different drugs and therapies involved in Breg induction in vivo.

---

**TABLE 1 | Breg Human Cellular markers and Effector molecules.**

| Human regulatory B cell markers | Markers | Reference |
|---------------------------------|---------|-----------|
| Transitional or Immature B10 cells | CD1d<sup>hi</sup>B10 | Blair et al. (2010); Zhang et al. (2012); Flores-Borja et al. (2013); Khoder et al. (2014); Liu et al. (2016) |
| CD10<sup>hi</sup>B10 cells | CD19<sup>CD44<sup>CD38<sup>IL-10<sup> | Yanaba et al. (2008); Bankoti et al. (2012); Zhang et al. (2012); van der Vlugt et al. (2014); Khan et al. (2015a) |
| Memory B10 Cells | CD19<sup>CD20<sup>CD27<sup>IL-10<sup> | Iwata et al. (2011); Salomon et al. (2017); Hasan et al. (2019) |
| B1 Cells | CD19<sup>CD25<sup>CD71<sup>CD73<sup> | Kubo et al. (2012); Kim et al. (2016)|
| Plasmablasts | CD19<sup>CD27<sup>CD38<sup> | Matsumoto et al. (2014); Shen et al. (2014) |
| Circulating B cells | CD19<sup>CD9<sup> | Hagn and Jahrsdörfer (2012); Hagn et al. (2012); Lindner et al. (2013); Chesneau et al. (2015); Durand et al. (2015); Zhu et al. (2017); Sun et al. (2015); Brosseau et al. (2018a); Brosseau et al. (2018b); Mohd Jaya et al. (2021) |
| CD9<sup>B cells | CD19<sup>CD9<sup> | Kessel et al. (2012) |
| GMZB<sup>B cells | CD19<sup>GMZB<sup> | Hasan et al. (2021) |
| CD73<sup>B cells | CD19<sup>CD73<sup> | | |
| CD73<sup>B cells | CD19<sup>CD73<sup> | | |
| CD9<sup>B cells | CD19<sup>CD9<sup> | | |
| CD73<sup>B cells | CD19<sup>CD73<sup> | | |
| TIGIT<sup>memory B cells | CD24<sup>HiCD27<sup>TIGIT<sup> | Hasan et al. (2021) |

| Human Regulatory B Cell Effector Molecules | Key Features | Reference |
|-------------------------------------------|--------------|-----------|
| IL-10 | Induce Treg, maintain NKT homeostasis, supress effector T cells Modulates plasmacytoid dendritic cells and macrophage and function CD9 and Tim-1 are strongly associated to IL-10 production | Yanaba et al. (2009); Mauri and Bosma (2012); Lykken et al. (2015); Lighaam et al. (2018) |
| IL-35 | Promotes IL-35 and Il-10 production by Treg and Breg Inhibits pathogenic Th1 and Th17 responses | Shen et al. (2014); Wang et al. (2014); Choi and Egwuagu (2021) |
| PD-L1 | Inhibits T cell activation and differentiation by binding PD-1 | Khan et al. (2015b); Wang et al. (2019); Lundy and Boros (2002); Lundy and Fox (2009); Tang et al. (2016); Wang et al. (2017) |
| FASL | Induces T cell apoptosis by binding FAS | Natarajan et al. (2012); Lee et al. (2014) |
| TGF-β | Enhances Treg and Breg induction Inhibits Th1 differentiation by inhibiting STAT4 | Hagn and Jahrsdörfer (2012); Hagn et al. (2012); Lindner et al. (2013); Chesneau et al. (2020) |
| GZMB | Induces T cell apoptosis and strongly suppress T cell proliferation by degradation of the T-cell receptor ζ-chain Present in several B cell subsets, in peripheral, most commonly found in plasmablasts | Hagn and Jahrsdörfer (2012); Hagn et al. (2012); Lindner et al. (2013); Durand et al. (2015); Zhu et al. (2017); Chesneau et al. (2020) |
| CD73 | Supresses effector T cell function by producing adenosine. CD73 catalyses the dephosphorylation of adenine to adenosine | Saze et al. (2013); Kaku et al. (2014) |
| IDO | Promotes Treg and Breg differentiation | Nouli et al. (2015) |

Breg: Regulatory B cell, Br1: Type 1 Regulatory B cell, B10: IL-10-producing regulatory B cells, GZMB: Granzyme B, IDO: indoleamine 2,3-dioxygenase.
Pharmacological Interventions

The use of immunosuppressive regimes combining different drugs has become a staple of clinical transplantation. For the most part, classical immunosuppressive interventions have little to no effect over B cells, and they have shown not to be active inducers of Breg cells with few exceptions.

Starting from classical immunosuppressive regimes, corticosteroids and calcineurin inhibitors (CNI) mildly reduce the number of total naïve and transitional B cells in renal transplant patients, with the exception of tacrolimus having no effect on B cell subsets (Latorre et al., 2016; Rebollo-Mesa et al., 2016; Tebbe et al., 2016; Bottomley et al., 2017).

In patients with IgA vasculitis that had impaired Breg function, the treatment with glucocorticoid prednisolone, promoted an increase in CD5+CD1d+, CD5+CD1d+ IL-10+, and IL-10+ B cell subsets, accompanied by an increase in the serum IL-10 concentration (Hu et al., 2016). However, in Lupus Nephritis patients, same treatment with prednisolone correlated with lower percentages of IL10+ B cells (Heinemann et al., 2016).

While low to medium doses of mycophenolate mofetil increase Breg subsets, high doses of mycophenolate reduce both B cell IL-10 and CD80/86 expression on B cells in kidney transplant patients. (Matz et al., 2012; Joly et al., 2014; Rebollo-Mesa et al., 2016; Bottomley et al., 2017).

The effect of mTOR inhibitors over Breg subsets has not been clearly established. In kidney transplanted patients sirolimus reduced Transitional B cell populations, while in another report in liver transplant patients, it was described to induce Breg when patients were converted to sirolimus from a tacrolimus based regime (Latorre et al., 2016; Song et al., 2020).

Also the effect of the 6-mercaptopurine analog, Azathioprine, on Bregs has been studied, and it’s know to reduce total, naïve and transitional B cells (Rebollo-Mesa et al., 2016; Bottomley et al., 2017).

The B cell depleting agent rituximab induces rapid depletion of CD20+ B cells after administration in a dose-dependent manner, lasting as long as 6 months, followed by a slow recovery (Bergantini et al., 2020). Breg frequencies decrease after administration of the drug, while long term effect of rituximab seems to indirectly stimulate bone marrow to produce transitional B cells when B cells are depleted, coupled with a substantial reduction in CD27+ B (memory) cells at long-term follow-up (Moller et al., 2009; Rehnberg et al., 2009).

The costimulation blocker Belatacept has shown promising results in kidney transplanted patients regarding Breg induction. Belatacept increases IL-10 expression and transitional populations, while reducing plasmablast differentiation (Leibler et al., 2014; Xu et al., 2020).

Finally, common induction therapies, such as basiliximab (chimeric anti-CD25) and Thymoglobulin (anti-thymocyte globulin) show no effect over transitional B cells (Longshan et al., 2014; Alfaro et al., 2021) while CAMPATH-1H (anti-CD52) increased transitional B cells and reduced memory B cells (Thompson et al., 2010; Heidt et al., 2012; Cherukuri et al., 2021).

Other immunomodulatory drugs have been described to induce Breg, such as tocilizumab (anti-IL-6) (Assier et al., 2010; Snir et al., 2011), Fingolimod (sphingosine-1-phosphate receptors modulator) (Grützke et al., 2015) and Laquinimod (quinolone-3-carboxiamide) (Toubi et al., 2012).

Cell and Extracellular Vesicles Therapies

Cell therapies earned a lot of interest as a new approach to induce immunosuppression and tolerance, with an increased presence in clinical trials during the last decade.

Mesenchymal stromal/stem cells (MSC) therapy has been at the forefront of cell therapies in the field of transplantation due to their immunomodulatory and regenerative properties (Pittenger et al., 1999). MSC interact with several cell types, including B cells, inducing regulatory B cells while abrogating plasmablast induction, B cell terminal differentiation and inhibiting antibody production (Comoli et al., 2007; Asari et al., 2009; Guo et al., 2013; Franquesa et al., 2015; Guth et al., 2017; Perico et al., 2018; Chen et al., 2019, 2023). The effect and mechanisms of MSC immunomodulatory action on Bregs has been extensively reviewed (Liu et al., 2020).

A promising alternative to MSC cell therapies are extracellular vesicles (MSC-EVs), reviewed in (Gomzikova et al., 2019; Gowen et al., 2020). EVs emululate parental cell properties, MSC-EVs stimulate tissue regeneration and immune modulation and have been proposed to tackle many diseases including kidney diseases and kidney graft rejection. MSC-EVs have been described in vitro to be mediators of Breg induction in a dose dependent manner (Budoni et al., 2013). However, MSC-EV involvement in Breg induction is a complex topic as the EV isolation method used might produce opposite effects as we previously described (Carreras-Planella et al., 2019). Highly purified MSC-EV displayed reduced immunomodulatory capabilities on B cells compared to MSC soluble protein enriched fractions.

In addition to MSC, other cell therapies have been tested and described to induce Breg. Regulatory T cells (Treg) therapy using autologous T cells in kidney transplant patients has been associated with a long-lasting dose-dependent increase of marginal B zone B cells, which are associated with IL-10 production and regulation (Harden et al., 2021). In a different study in a mouse model, CAR-Treg specific to the B cell marker CD19 (Imura et al., 2020) suppressed IgG antibody production and differentiation of B cells in a TGF-β-dependent manner. Regulatory T and B cells work in harmony to stabilize homeostasis, and both promote each other induction and expansion as seen in different mouse models (Lee et al., 2014; Wang et al., 2015; Chien and Chiang, 2017) via IL-10 and TGF-β.

Tolerogenic Dendritic cells (tolDC) are essential for the induction of Breg in humans and their administration has been described to induce Breg (Boldison et al., 2020). No clinical trials have been performed in kidney transplant patients, but in a phase one safety study in diabetic patients, tolDC increased the frequency of regulatory B cells (Giannoukakis et al., 2011).

Indirect Intervention: The Role of Microbiota

Previous methods described to induce Bregs focus on tackling the specific either cellular or molecular pathways involved in the maintenance or induction of Breg, but a different approach with
Growing interest during recent years is to promote balanced stress-free metabolic and immune balance.

In this context, an alternative approach to promote graft tolerance and improve patients’ quality of life, most likely in combination with previous drug interventions and/or cell therapies, would be focus on metabolic interventions by modulation of gut microbiota or other metabolic pathways.

Gut microbiota and dysbiosis are linked to adverse events, reduced quality of life, and an increase of graft rejection in kidney transplanted patients (Lee et al., 2019; Swarte et al., 2020; Pacaud et al., 2021). Gut microbiota interacts with the immune system generating a balance of inflammatory and regulatory responses that maintain the homeostasis with metabolic and immune system effects outside the gut, including the generation of Bregs. B cells have the capability to recognize different bacterial and viral elements by the BCR and TLRs (Gallego-Valle et al., 2018; Mu et al., 2020; Pacaud et al., 2021) and also cytokines and metabolites derived from these microbes, such as short chain fatty acids (SCFAs) (Rosser et al., 2020; Daïen et al., 2021; Pacaud et al., 2021; Zou et al., 2021) expanding Breg subsets. Recent studies have elucidated the role of the SCFA pentanoate in the modulation of mTOR activity, leading to a significant boost of IL-10 production by LPS or CpG stimulated Breg, and a substantial reduction of B cell apoptosis, in addition to reducing expression of IL-17A in effector T cells by inhibiting HDAC (histone deacetylase) activity via epigenetic modulation (Luu et al., 2019). In a different study, direct inhibition of HDAC by Entinostat, an HDAC inhibitor, increased IL-10 production by LPS-stimulated B cells. Entinostat activity prevented HDAC binding to the proximal region of the IL-10 expression promoter, increasing binding of NF-κB p65, and enhancing IL-10 expression (Min et al., 2021).

**IBREG CELL THERAPY: IS IT FEASIBLE**

Cell therapy is not a new concept anymore and protocols and clinical trials are being set up to promote tolerance in autoimmune diseases and transplantation in the absence or in a minimized immunosuppressive regime. MSC therapy has taken the lead in this area with several clinical trials already published. In parallel, regulatory immune cell types such as Tregs or tolDCs are the main not-modified immune cell types being studied and used for cell therapy in immune mediated diseases and regenerative approaches. Therefore, the idea of a cell therapy product involving Bregs might sound promising although, to this moment, there are no trials on the use of Breg as a cell therapy.

The incomplete knowledge on Breg induction and or expansion, stability, and functional potential and the lack of a consensus Breg signature are just some of the hurdles to be bypassed to generate a safe and efficient cell product. Moreover, we might be dealing with different subsets of Breg depending on the induction cocktail and system used that might present different stability and functionality. We are going in depth on it in the next *In Vitro Breg induction (iBregs)*.

Another matter of concern is the antigen specificity of Breg. Recent studies provide evidence for an essential role of antigen recognition by B cells to generate allograft tolerance in murine models (Kimura et al., 2020; Mohib et al., 2020) and in this line, the critical role of BCR and CD40 expression for Breg development and in transplant models is proven. On the other hand, TGF-β seems to mediate a prominent role in allograft survival (Kimura et al., 2020) while IL-10 essentiality in mediating Breg tolerogenic action is questioned. Insight in the role of Breg antigen specificity may bring the development of chimeric antigen receptor (CAR)-lymphocyte generation to produce cellular therapies with targeted Bregs.

Bregs have also been shown to represent a significant source of serum IgM and IgG during adoptive transfer experiments, and produce antigen-specific, polyreactive and autoreactive antibody specificities (Lo-Man, 2011). However, their role in solid organ transplantation still needs to be defined and new technical advances in nanosciences might bring new opportunities into that area.

The effect that donor or recipient-derived Breg could have in modulating the immune reaction remains unknown if we envision a therapy with autologous or allogeneic Breg in autoimmune diseases or organ transplantation. And as in every cell therapy donor origin (autologous or allogeneic) needs to be carefully considered. The age of the patient appears to be a relevant factor in the capacity of Bregs to produce IL-10 since it is impaired in CD38HiCD24Hi B cells from old individuals (Duggal et al., 2013). Also, autoimmune diseases have been related to disfunctional Bregs where patient’s Breg numbers are normal but they lack the immunomodulatory properties related to this cell “subset” and furthermore, Bregs isolated from patients who had suffered renal graft rejection lost their inhibitory capacity (Nouel et al., 2014). This might be a major problem if we think of autologous cell treatment. There are other mechanistic issues that would have to be addressed such as the time needed to produce enough Breg, infusion timing and dosage, route of administration, and GMP compliance.

**In Vitro Breg Induction (iBregs)**

The implementation of a reliable and reproducible method of *in vitro* Breg induction and expansion from human B cells is highly required for the development of Breg-based cell therapies. The application of a standardized *in vitro* induction method which generates a well-characterized subset of induced Bregs could compensate for the absence of a human Breg biomarker.

Traditional mechanisms of iBregs induction are mostly based on the stimulation of Toll-like receptors 4 and 9 (TLR4 and TLR9) by bacterial-derived LPS and CpG molecules and the ligation of B-cell antigen receptor (BCR) and CD40 to agonist molecules. In this sense, signaling pathways triggered by TLRs and CD40 accompanied by BCR stimulation might lead to IL-10 production, a conventionally used cytokine for the assessment of *in vitro* Breg induction, via activation of transcription factors such as STAT3 (Baba et al., 2015). However, there is also evidence of B cell activation towards effector and/or memory phenotypes when using such strong stimulation methods, and therefore inflammatory cytokines should also be carefully monitored in these induction systems (Lighaam et al., 2018).
Besides IL-10, several groups have described other molecules as key mediators of iBreg regulatory potential. Several “non-classic” Breg markers have been explored, such as the Granzyme B (GZMB) molecule. Currently, the population of GZMB-expressing B cells is represented as a particular subset of Bregs. In addition, a reproducible protocol for the in vitro expansion of this cell subset is already reported in the literature (Chesneau et al., 2020).

As we mentioned in Indirect Intervention: The Role of Microbiota, the use of SCFAs is being developed in an attempt to mimic the gut microbiota action. This method would be considered an additional novel form of in vitro Breg induction as an alternative to boosting the patient’s natural gut microbiota.

Leaving aside the traditional methods and the use of bacterial compounds, our group described the co-culture of tonsil derived-B cells and MSCs from subcutaneous fat as a method of inducing the development of Bregs (Franquesa et al., 2015; Luk et al., 2017).

Common to all the aforementioned methodology, it would be necessary to establish a protocol for the generation of iBregs with a stable phenotype over time. In this regard, the Breg marker CD9 has already been shown to be highly modulated (Mohd Jaya et al., 2021). Therefore, phenotypic and functional stability is a challenge considering the transient nature of some of the Breg phenotypes described (Table 1).

**DISCUSSION**

In this mini-review we aimed to summarize the most relevant and recent evidence on the role of Bregs in kidney disease by discussing the relevance of in vitro and in vivo Breg induction as well as the potential use of Bregs as cell therapy agents (Figure 1). Bregs have been described as major drivers of tolerance in kidney transplantation and in autoimmune diseases. Their upregulated expression has been related to spontaneous tolerant kidney transplant patients, while impaired function and low numbers of Bregs have been associated to several autoimmune diseases.

Breg homeostasis appears to be a cornerstone for immune regulation and tolerance, so several tactics are being approached to reestablish the equilibrium lost in several pathological situations.

One approach is to boost natural Breg populations in patients. Regardless of the limited knowledge of markers, there is already a description of the effect of every immunosuppressant used in kidney transplantation and other anti-inflammatory drugs on Breg populations, allowing for a possible optimization of Breg-induced tolerance. In this line, some immunosuppressants such as Belatacept or Campath, have shown to boost Breg in kidney transplant patients.

Such Breg boosting therapies could be coadjuvant of cellular therapies with MSC or Tregs which have shown capacity to induce Bregs in kidney transplant patients. TolDC have shown similar results in diabetic patients, but have not been tested in clinical trials for kidney transplant. Furthermore, indirect metabolic interventions are slowly gaining track on the field, with increasing publications about the role of gut microbiota and dysbiosis in the maintenance of homeostasis and immune balance, opening new fields of research and clinical research.

On the other hand, Breg application as adoptive cellular therapy is a contentious topic, with no clinical trials on the horizon, due to their difficult identification and expansion. In human, Breg are niche populations in peripheral blood with low expression, with most of them being localized in the spleen, so...
in vitro expansion would be necessary to achieve significant therapeutic effects. The lack of consensus on several key points such as; Breg signature, antigen specificity, alloreactivity, expansion system, stability after administration and dosage, would be critical in the efficacy of such therapy.

In recent years, there has been extensive progress in the understanding of Bregs, many researchers are pursuing the definitive human Breg signature, however this seems rather utopic. Many different markers have been associated to Bregs and iBregs, opening new doors for their expression of FasL or PD-L1 have also been described as key markers of Bregs and iBregs, opening new doors for their mechanistic paths of regulation.

However, the development of improved in vitro Bregs induction systems from human B cells, such as the use of SCFAs or MSCs, opens up the possibility of re-educating the patient’s B cells towards a regulatory phenotype and presents a small ray of hope in the context of adoptive Bregs therapy. The ideal in vitro induction system should generate, from donor B cells, a sufficient number of iBregs with a stable phenotype and a demonstrable immunomodulatory capacity.

**AUTHOR CONTRIBUTIONS**

SGG, NS-H, and MF summarized the literature and drafted the manuscript. All authors reviewed and approved the final manuscript.

**FUNDING**

This work was supported in part by SGR program of Generalitat de Catalunya (2017-SGR-301 REMAR Group) and Instituto Carlos III project PI17/000335, integrated in the National R + D + I and funded by the ISCIII and the European Regional Development Fund. SGG is supported by the Catalan Health department (“Departament de Salut”) in receipt of a grant from PERIS-PIF-Salut (SLT017/20/000158), and MF is supported by ISCIII (MS19/00018), co-funded by ERDF/ESF, “Investing in your future”.

**REFERENCES**

Alfaro, R., Legaz, I., González-Martínez, G., Jimenez-Coll, V., Martínez-Banalocha, H., Gallán, J. A., et al. (2021). Monitoring of B Cell in Kidney Transplantation: Development of a Novel Clusters Analysis and Role of Transitional B Cells in Transplant Outcome. Diagnostics (Basel) 11, 641. doi:10.3390/diagnostics11040641

Aravena, O., Ferrier, A., Menon, M., Mauri, C., Aguillón, J. C., Soto, L., et al. (2017). TIM-1 Defines a Human Regulatory B Cell Population that Is Altered in Frequency and Function in Systemic Sclerosis Patients. Arthritis Res. Ther. 19, 8. doi:10.1186/s13075-016-1213-9

Asari, S., Itakura, S., Ferreri, K., Liu, C. P., Kuroda, Y., Kandeel, F., et al. (2009). Mesenchymal Stem Cells Suppress B Cell-Terminal Differentiation. Exp. Hematol. 37, 604–615. doi:10.1016/j.exphem.2009.01.005

Asier, E., Boissier, M. C., and Dayer, J. M. (2010). Interleukin-6: From Identification of the Cytokine to Development of Targeted Treatments. J. Bone Spine 77, 532–536. doi:10.1016/j.jbspin.2010.07.007

Baba, Y., Matsumoto, M., and Kurosaki, T. (2015). Signals Controlling the Development and Activity of Regulatory B-Lineage Cells. Int. Immunol. 27, 487–493. doi:10.1093/intimm/dxv027

Bankoti, R., Gupta, K., Levchenko, A., and Stäger, S. (2012). Marginal Zone B Cells License Regulatory B Cells to Produce IL-10 and Mediate Suppression of Cytokine to Development of Targeted Treatments. Immunology. 139, 1415–1421. doi:10.1111/j.1365-2958.2010.03996.x

Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. (2014). Mesenchymal Stem Cells Suppress B-Cell Terminal Differentiation. J. Immunol. 192, 2359–2366. doi:10.4049/jimmunol.1301920

Bottomley, M. J., Chen, M., Fuggle, S., Harden, P. N., and Wood, K. J. (2017). Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study. Transplant. Direct 3, e125. doi:10.1097/TXD.0000000000000638

Brousse, C., Colas, L., Magnan, A., and Brouard, S. (2018a). CD9 Tetraspanin: A New Pathway for the Regulation of Inflammation? Front. Immunol. 9, 2316. doi:10.3389/fimmu.2018.02316

Brousse, C., Durand, M., Colas, L., Durand, E., Fourneau, A., Cheminant, M. A., et al. (2018b). CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients. Front. Immunol. 9, 3034. doi:10.3389/fimmu.2018.03034

Budoni, M., Ferrabbracci, A., Luciano, R., Petrini, S., Di Ciommo, V., and Muraca, M. (2013). The Immunosuppressive Effect of Mesenchymal Stromal Cells on B Lymphocytes Is Mediated by Membrane Vesicles. Cell Transpl. 22, 369–379. doi:10.3727/096368913X582769

Cai, X., Zhang, L., and Wei, W. (2019). Regulatory B Cells in Inflammatory Diseases and Tumor. Int. Immunopharmacol. 67, 281–286. doi:10.1016/j.intimp.2018.12.007

Carreras-Planella, L., Monguió-Tortajada, M., Borràs, F. E., and Franquesa, M. (2019). Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted Extracellular Vesicles. Front. Immunol. 10, 1288. doi:10.3389/fimmu.2019.01288

Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinik, K., Aguillón, J. C., et al. (2021). Immunosuppressive Mechanisms of Regulatory B Cells. Front. Immunol. 12, 611795. doi:10.3389/fimmu.2021.611795

Chen, X., Cai, C., Xu, D., Liu, Q., Zheng, S., Liu, L., et al. (2019). Human Mesenchymal Stem Cell-Treated Regulatory CD23+CD43+ B Cells Alleviate Intestinal Inflammation. Theranostics 9, 4633–4647. doi:10.7150/thno.32260

Cherukuri, A., Mohib, K., and Rothstein, D. M. (2021). Regulatory B Cells: TIM-1, Transplant Tolerance, and Rejection. Immunol. Res. 299, 31–44. doi:10.1111/imr.12933
